Drugs / rFVIIa
rFVIIa
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00222625 | Sep 2005 → Sep 2006 | intracerebral hemorrhage | University Of Perugia | Unknown | No outcome recorded |
| Phase 42 trials · 1 met primary | ||||||
| Phase 4 | NCT00370877 | Apr 2007 → Nov 2010 | — | Nîmes University Hospital | Completed | Met primary |
| Phase 4 | NCT00284193 | Jan 2005 → Nov 2008 | hemophilia A | Sheba Medical Center | Completed | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 2 | NCT01359202 Comparator | May 2011 → Jun 2018 | stroke disorder | Dr. David Gladstone | Completed | No outcome recorded |
| Phase 3 | NCT04563520 Background | Jun 2026 → Mar 2027 expected | hemophilia A | Emory University | Recruiting | No outcome recorded |
| Phase 3 | NCT02622321 Background | Nov 2015 → Oct 2016 | hemophilia A | Hoffmann-La Roche | Completed | Met primary |
Press releases naming this drug 2 releases
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rFVIIa | “To investigate whether recombinant activated coagulation factor VII (rFVIIa) reduces hemorrhage expansion among patients with spot sign-positive ICH.” PMID 31424491 ↗ Dec 2019 |
| Known as | Factor VIIa | “rFVIIa (recombinant activated factor VIIa; 80 μg/kg)” PMID 36756899 ↗ Feb 2023 |
| Known as | recombinant activated coagulation factor VII | “To investigate whether recombinant activated coagulation factor VII (rFVIIa) reduces hemorrhage expansion among patients with spot sign-positive ICH.” PMID 31424491 ↗ Dec 2019 |
| Known as | recombinant activated factor VII | “nine RCTs of recombinant activated factor VII (rFVIIa) versus placebo/open control” PMID 37870112 ↗ Oct 2023 |
| Known as | recombinant activated factor VIIa | “rFVIIa (recombinant activated factor VIIa; 80 μg/kg)” PMID 36756899 ↗ Feb 2023 |
| Known as | recombinant factor VIIa | “Evaluation of efficacy and safety of recombinant factor VIIa versus standard therapy in preventing early haematoma growth” NCT00222625 ↗ |
| Known as | recombinant human factor VIIa | “Case reports on recombinant human factor VIIa (rhuFVIIa) use in women with severe postpartum hemorrhage (PPH) showed encouraging results” PMID 25594352 ↗ Mar 2015 |
| Modality | Protein / enzyme biologic | “nine RCTs of recombinant activated factor VII (rFVIIa) versus placebo/open control” PMID 37870112 ↗ Oct 2023 |
| Route | Intravenous | “IV infusion of rFVIIa” NCT00370877 ↗ |